The Commission today adopted a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU pharmaceutical industry. The strategy will enable Europe to cover its pharmaceutical needs, including in times of crisis, with strong supply chains. A key component of building a stronger European Health Union, as called for by the President von der Leyen in its speech on the situation in the Union, the Strategy will help to establish a future and crisis-resistant EU pharmaceutical system.
The European Pharmaceutical Strategy has four main objectives:
- Insurance access affordable medicines for patients and addressing unmet medical needs (e.g. in areas of antimicrobial resistance, cancer, rare diseases);
- Support competitiveness, innovation and sustainability the EU pharmaceutical industry and the development of high quality, safe, effective and greener medicines
- Improvement crisis preparedness and response mechanisms and addressing security of supply;
- Insurance a the strong voice of the EU in the world, by promoting a high level of quality, efficiency and safety standards.
Although the Strategy is much more than a crisis response instrument, it draws lessons from the initial response to the COVID-19 pandemic and makes the European pharmaceutical sector better. prepared and more durable.
The strategy presents concrete measures to be provided availability, availability and affordability of medicines. It supports diversified and secure supply chains, ensuring the EU’s open strategic autonomy in the world and promoting environmentally sustainable pharmaceutical products.
The strategy will also ensure that EU pharmaceutical policy continues to serve public health in a continuous environment of scientific and commercial transformation. He will support patient-centered innovation and accommodate digital and technological change.
College members said
President of the European Commission, Ursula von der Leyen, stated: “The coronavirus pandemic highlighted the vital need to strengthen our health systems. This includes access to safe, effective and high-quality medicines at an affordable price. In the challenging economic and social times that the EU is currently facing, the strategy adopted today will ensure that Europe and Europeans continue to benefit from such medicines. I call on the Member States and Parliament to support this approach, which will be applied over the next three years and beyond. “
Vice-President for the Promotion of the European Way of Life, Margaritis Schinas, He said: “Effective and safe medications, vaccines and treatments have helped address some of the leading causes of life-threatening and life-threatening illnesses in the past. These products will be crucial to preserving the health and well-being of European citizens in these challenging times. Today’s strategy supports the EU pharmaceutical industry to remain competitive and innovative, while meeting the needs of patients and our health systems. “
Stella Kyriakides, The Commissioner for Health and Food Safety, emphasized: “Today, we are starting to work to ensure that safe and effective medicines are available and accessible at all times and to all patients across the EU. With our pharmaceutical strategy for Europe, we are fulfilling our commitment to creating a future-oriented and patient-oriented pharmaceutical environment in which the EU industry can innovate, flourish and continue to be a global leader. It is our long-term vision of open strategic autonomy and our response to today’s challenges and vulnerabilities exposed to COVID-19. Today we set up another pillar of the European Health Union. “
The European Pharmaceutical Strategy marks the beginning of the process: its implementation involves an ambitious program of legislative and non-legislative actions which will be launched in the coming years.
The actions will cover the entire ecosystem of pharmaceutical products, but also some aspects of medical products. It creates synergies with the Green Treaty and our activities towards the EU Strategic Approach to Environmental Pharmaceuticals to reduce their risk to the environment, address pollution from pharmaceutical residues and promote greener production, use and disposal (progress report available). It is also linked to the Intellectual Property Action Plan presented today.
The leading actions Strategies include:
- Revision of basic pharmaceutical legislation * (target proposal date: 2022) with a view to making this framework future and innovative;
- Proposal for an EU emergency health authority (proposal: 2nd semester 2021);
- Revision of regulations on medicines for children and rare diseases
- Initiate a structured dialogue with and between all actors in the pharmaceutical industry and public authorities to identify vulnerabilities in the global supply chain of critical medicines and to shape policy options to strengthen the continuity and security of supply in the EU;
- Cooperation between national authorities on pricing, payment and procurement policies to improve the affordability, cost-effectiveness of medicines and the sustainability of the health system;
- Creating a robust digital infrastructure, including a proposal for a European Health Data Area (target proposal date: 2021);
- Support for research and innovation, in particular through Horizon 2020 and EU4Health;
- Actions to promote innovative approaches to EU research and development and public procurement of antimicrobials and their alternatives and measures to limit and optimize their use.